Invitris
Creating new protein-based drugs at scale
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined. Invitris is a Y Combinator company (Winter 2023). YC-listed status: Active.
- Website
- invitris.com
- Location
- Munich, BY, Germany
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Invitris — Cell-free protein synthesis platform for rapid design, expression, and scalable production of complex proteins without living cells. · Other
Links
- Y Combinator profileycombinator